PRODUCTS & SERVICES
Ivan Stefanec, a Member of the European Parliament, visited MultiplexDX and took a tour with our CEO and management team through our labs and offices to see where we do our research and develop revolutionary technologies for personalized molecular diagnostics.
We are proud to host such remarkable guests who share the same values and principles and agree that innovation is key to accelerating the economy of tomorrow.
Thank you very much for coming!
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter